Literature DB >> 3392651

Types of interaction of amphiphilic drugs with phospholipid vesicles.

U M Joshi1, P R Kodavanti, B Coudert, T M Dwyer, H M Mehendale.   

Abstract

Binding characteristics of nine amphiphilic drugs, which induce pulmonary phospholipidosis, to L-alpha-dipalmitoyl phosphatidylcholine (DPPC) vesicles were studied using fluorescence probes, 1,6-diphenyl-1,3,5-hexatriene and 1-anilino-8-naphthalene sulfonate (ANS) for hydrophobic and hydrophilic interactions, respectively. Drug binding to DPPC was quantitated using Scatchard analysis. The tested drugs bound to DPPC with different capacities. The order of binding capacity to hydrophobic site of DPPC using 1,6-diphenyl-1,3,5-hexatriene as fluorescence probe was promethazine greater than amiodarone greater than chlorpromazine greater than chloramphenicol greater than imipramine greater than trimipramine greater than propranolol much greater than chloroquine and chlorphentermine. Two binding affinities were evident for amiodarone, chlorpromazine, imipramine, trimipramine and promethazine. The order of binding strength at high affinity site was amiodarone greater than trimipramine greater than chlorpromazine greater than promethazine greater than imipramine. The order of drug binding capacity using ANS as fluorescence probe was chlorphentermine greater than trimipramine greater than propranolol much greater than amiodarone, chloroquine and chloramphenicol. Each of these drugs displayed a single binding affinity. Imipramine and chlorpromazine at 1 mM and higher concentrations showed intense fluorescence with ANS (5-20 microM) in the absence of DPPC indicating an interaction of these drugs with ANS. Chloroquine did not bind to either sites on DPPC. The binding of these drugs and their interactions with hydrophobic or hydrophilic sites of DPPC were correlated with their capacity to induce pulmonary phospholipidosis. These results indicate that not all the drugs which bind to DPPC in vitro induce phospholipidosis in vivo.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3392651

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

1.  Amiodarone--induced changes in surfactant phospholipids of rat lung.

Authors:  B Padmavathy; H Devaraj; N Devaraj
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-04       Impact factor: 3.000

2.  Predicting the mechanism of phospholipidosis.

Authors:  Robert Lowe; Hamse Y Mussa; Florian Nigsch; Robert C Glen; John Bo Mitchell
Journal:  J Cheminform       Date:  2012-01-26       Impact factor: 5.514

3.  Amoxillin- and pefloxacin-induced cholesterogenesis and phospholipidosis in rat tissues.

Authors:  Solomon O Rotimi; David A Ojo; Olusola A Talabi; Regina N Ugbaja; Elizabeth A Balogun; Oladipo Ademuyiwa
Journal:  Lipids Health Dis       Date:  2015-02-21       Impact factor: 3.876

4.  Alterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease.

Authors:  Emmanuelle Lecommandeur; David Baker; Timothy M Cox; Andrew W Nicholls; Julian L Griffin
Journal:  J Lipid Res       Date:  2017-04-04       Impact factor: 5.922

5.  Development of a Potent Antimicrobial Peptide With Photodynamic Activity.

Authors:  Di Zhang; Jingyi Chen; Qian Jing; Zheng Chen; Azeem Ullah; Longguang Jiang; Ke Zheng; Cai Yuan; Mingdong Huang
Journal:  Front Microbiol       Date:  2021-06-01       Impact factor: 5.640

6.  Amiodarone hepatotoxicity with absent phospholipidosis and steatosis: a case report and review of amiodarone toxicity in various organs.

Authors:  Adela Cimic; Joseph Sirintrapun
Journal:  Case Rep Pathol       Date:  2013-05-20

7.  Identification of drugs inducing phospholipidosis by novel in vitro data.

Authors:  Markus Muehlbacher; Philipp Tripal; Florian Roas; Johannes Kornhuber
Journal:  ChemMedChem       Date:  2012-09-03       Impact factor: 3.466

8.  In Vitro Assessment of Uptake and Lysosomal Sequestration of Respiratory Drugs in Alveolar Macrophage Cell Line NR8383.

Authors:  Ayşe Ufuk; Graham Somers; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2015-07-30       Impact factor: 4.200

Review 9.  The surfactant system of the adult lung: physiology and clinical perspectives.

Authors:  H Hamm; H Fabel; W Bartsch
Journal:  Clin Investig       Date:  1992-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.